Clinical Trials
62
Active:3
Completed:11
Trial Phases
5 Phases
Early Phase 1:4
Phase 1:8
Phase 2:7
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Not Applicable
24 (49.0%)Phase 1
8 (16.3%)Phase 2
7 (14.3%)Phase 4
6 (12.2%)Early Phase 1
4 (8.2%)Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Not Applicable
Recruiting
- Conditions
- New Diagnosed Angioimmunoblastic T-Cell Lymphoma
- Interventions
- Drug: tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Target Recruit Count
- 40
- Registration Number
- NCT07168317
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Not Applicable
Active, not recruiting
- Conditions
- Systemic Lupus ErythematosusSystemic Sclerosis
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Target Recruit Count
- 18
- Registration Number
- NCT07155369
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction
Not yet recruiting
- Conditions
- AMI
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Target Recruit Count
- 1112
- Registration Number
- NCT07138638
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Not Applicable
Not yet recruiting
- Conditions
- TenofovirChidamideLenalidomideEpstein-Barr Virus (EBV) InfectionPD-1 Inhibitor
- Interventions
- Drug: PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Target Recruit Count
- 30
- Registration Number
- NCT07133776
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
Not Applicable
Not yet recruiting
- Conditions
- LenalidomideEBV-Associated Lymphoproliferative DisordersPD-1 InhibitorTenofovirChidamide
- Interventions
- Drug: PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Target Recruit Count
- 50
- Registration Number
- NCT07133763
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
No news found